Cramer was bearish on Alcoa (AA).
Cancer Treatment Breakthrough?
In his second "Executive Decision" segment, Cramer sat down with Daniel Junius, president and CEO of ImmunoGen (IMGN - Get Report), a speculative biotech developing the next generation of cancer-fighting drugs. ImmunoGen just received Food and Drug Administration approval for its latest breast cancer drug, T-DM1.
Junius said T-DM1 is a big breakthrough in breast cancer treatments and the drug should be available to patients within the next two weeks. He said it's exciting for both its therapeutic value but also because it will provide ImmunoGen a steady revenue stream for its other drugs in the pipeline.
Among those other drugs are IMGN-853, which is in early-stage testing to treat ovarian cancer, and IMGN-901, to treat small-cell lung cancer. Junius said the 853 is an important compound for the company and could lead to other indications, while 901 is showing encouraging results in prolonging life where there hasn't been any new treatments in 25 years.Junius also stressed the importance of these early-stage trials. He explained that time is money for the company, so getting patients into studies quickly allows them to make important go or no-go decision early so they can focus on only the most promising compounds. Cramer called ImmunoGen one of the least hyped but still most important speculative biotech news out there for investors.